

It has long been recognized that effective delivery systems are preferred for chemotherapeutic agents. The present invention addresses this need. First, chemotherapeutic agents are attached to monoclonal antibodies; second, the antibody is combined with DNA to yield a stable heteropolymer; and, third, the drug-heteropolymer is injected in a therapeutically effective amount.